Blocking Risk-Factor Molecule Could Be Path To New COPD Treatment, Study Reports
Analyses showed that this disease patients and smokers who did not have COPD had higher levels of the membrane-bound form of the disease in their lungs than non-smoking healthy people. In contrast, patients and smokers had lower levels of soluble RAGE.
Analyses showed that blocking the molecule with a compound called FPS-ZM1 reduced lung emphysema and airway inflammation in mice with this disaese. The New COPD Treatment also reduced oxidative stress in the lungs. Oxidative stress is an imbalance between free radicals, which can damage cells, and the body’s anti-oxidant defense system, which fights free radicals.
Reduced inflammation occurred when the RAGE blocker prevented the activation of a pathway of New Copd Treatment that becomes activated in response to tissue damage, researchers said. Although such inflammatory events have beneficial features, they become hazardous in a chronic disease like this disease. Further experiments suggested that RAGE blocking path to New Copd Treatment affects only the inflammatory component of disease, and does not directly impact airway enlargement.
“RAGE disturbances in pulmonary disorders are precise and effective strategies with beneficial clinical effects,” Se-Ran Yang, PhD, the senior author of the study, said in a press release. He is an associate professor in the Kangwon School of Medicine’s Department of Thoracic and Cardiovascular Surgery.“[Our] data indicate for the first time that RAGE inhibition has an essential protective role in this disease.
Our observation of RAGE inhibition provided novel insight into its potential as a therapeutic target in emphysema/COPD,” the team concluded.Thoru Pederson, PhD, editor of The FASEB Journal, added that in COPD, the “current pharmacological armamentarium is limited, and studies like this are thus extremely valuable as a foundation.”